与利益相关者指导小组合作共同设计PRIME减药对话工具：反思与建议。 - Suppr | 超能文献

相似文献

1

Partnering with a stakeholder steering group to co-design the PRIME deprescribing conversation tool: Reflections and recommendations.与利益相关者指导小组合作共同设计PRIME减药对话工具：反思与建议。

Basic Clin Pharmacol Toxicol. 2024 Jan;134(1):121-125. doi: 10.1111/bcpt.13938. Epub 2023 Sep 8.

2

Co-Designing a Consult Patient Decision Aid for Continuation Versus Deprescribing Cholinesterase Inhibitors in People Living with Dementia.共同设计谘询患者决策辅助工具，以帮助患有痴呆症的患者继续或停止使用胆碱酯酶抑制剂。

Drugs Aging. 2024 Oct;41(10):821-831. doi: 10.1007/s40266-024-01146-5. Epub 2024 Sep 18.

3

How Should Clinicians Discuss Deprescribing with Caregivers of Older Adults Living with Dementia? A Qualitative Study.临床医生应如何与痴呆症老年患者的照顾者讨论减药问题？一项定性研究。

Drugs Aging. 2025 Feb;42(2):155-164. doi: 10.1007/s40266-024-01179-w. Epub 2025 Jan 19.

4

Designing a Primary Care-Based Deprescribing Intervention for Patients with Dementia and Multiple Chronic Conditions: a Qualitative Study.基于初级保健的痴呆和多种慢性病患者药物精简干预措施的设计：一项定性研究。

J Gen Intern Med. 2020 Dec;35(12):3556-3563. doi: 10.1007/s11606-020-06063-y. Epub 2020 Jul 29.

5

Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.在痴呆症中停用胆碱酯酶抑制剂和美金刚：指南摘要。

Med J Aust. 2019 Mar;210(4):174-179. doi: 10.5694/mja2.50015. Epub 2019 Feb 16.

6

Approaches to Deprescribing Psychotropic Medications for Changed Behaviours in Long-Term Care Residents Living with Dementia.为患有痴呆症的长期护理居民改变行为而停用精神药物的方法。

Drugs Aging. 2019 Feb;36(2):125-136. doi: 10.1007/s40266-018-0623-6.

7

Tools for deprescribing in severe dementia: A scoping review.用于严重痴呆症减药的工具：范围综述。

Int J Geriatr Psychiatry. 2023 Jul;38(7):e5959. doi: 10.1002/gps.5959.

8

[Deprescribing in Danish clinical treatment guidelines].[丹麦临床治疗指南中的减药]

Ugeskr Laeger. 2022 Jul 4;184(27).

9

Supporting conversations about medicines and deprescribing: GPs' perspectives on a Medicines Conversation Guide.支持关于药物及减药的对话：全科医生对《药物对话指南》的看法

Int J Pharm Pract. 2023 Mar 13;31(1):102-105. doi: 10.1093/ijpp/riac088.

10

Risk for Health Events After Deprescribing Acetylcholinesterase Inhibitors in Nursing Home Residents With Severe Dementia.在患有严重痴呆的养老院居民中停用乙酰胆碱酯酶抑制剂后的健康事件风险。

J Am Geriatr Soc. 2020 Apr;68(4):699-707. doi: 10.1111/jgs.16241. Epub 2019 Nov 26.

引用本文的文献

1

Use of an electronic medication management application to support Pharmacists Review to Optimise Medicines in Residential Aged Care (PROMPT-RC): a study protocol for a parallel cluster randomised controlled trial.使用电子药物管理应用程序支持药师审查以优化老年护理机构中的药物使用（PROMPT-RC）：一项平行整群随机对照试验的研究方案

BMJ Open. 2025 Jul 7;15(7):e097345. doi: 10.1136/bmjopen-2024-097345.

2

Co-Designing a Consult Patient Decision Aid for Continuation Versus Deprescribing Cholinesterase Inhibitors in People Living with Dementia.共同设计谘询患者决策辅助工具，以帮助患有痴呆症的患者继续或停止使用胆碱酯酶抑制剂。

Drugs Aging. 2024 Oct;41(10):821-831. doi: 10.1007/s40266-024-01146-5. Epub 2024 Sep 18.

3